Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma

Pediatr Blood Cancer. 2018 Jul;65(7):e27055. doi: 10.1002/pbc.27055. Epub 2018 Mar 30.

Authors

John A Heath¹, Marty A Campbell², Alison Thomas¹, Ben Solomon³

Affiliations

¹ Department of Pediatrics, Royal Hobart Hospital, Hobart, Australia.
² Department of Oncology, Royal Children's Hospital, Melbourne, Australia.
³ Department of Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia.

PMID: 29603581
DOI: 10.1002/pbc.27055

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Antineoplastic Agents / therapeutic use*
Carbazoles / therapeutic use*
Drug Resistance, Neoplasm / drug effects
Female
Humans
Neoplasm Recurrence, Local / drug therapy*
Neuroblastoma / drug therapy*
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use

Substances

Antineoplastic Agents
Carbazoles
Piperidines
Protein Kinase Inhibitors
alectinib